Navigation Links
Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
Date:9/26/2013

al diabetes molecules in Lilly's late-stage pipeline. The company has a number of potential new medicines in clinical development for the treatment of diabetes and its related conditions. Lilly expects to submit dulaglutide to regulatory authorities in 2013.

About the Study1,2
AWARD-1 was a randomised, 52-week, placebo-controlled comparison of the effects of dulaglutide and exenatide twice-daily on glycaemic control in patients with type 2 diabetes on metformin and pioglitazone. The primary objective of the study, conducted in 978 patients, was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, was superior to placebo in reducing HbA1c from baseline at 26 weeks.

To evaluate health outcomes, patients were administered questionnaires at baseline and again prior to follow-up visits at 26 and 52 weeks. Treatment satisfaction[*], as well as perceived hyperglycaemia and hypoglycaemia, were measured using the Diabetes Treatment Satisfaction Questionnaire (DTSQ); impact of weight was measured using the Impact of Weight on Self-Perception Questionnaire (IW-SP) and the Ability to Perform Physical Activities of Daily Living Questionnaire (APPADL); and perceived current health status was measured using the EuroQoL 5-Dimension Questionnaire (EQ-5D).

About Diabetes
Approximately 25.8 million Americans3 and an estimated 371 million people4 worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.5

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our cont
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
10. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- A new report by Allied Market ... End user, Application and Geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", considers commercial aspects ... trends tracked, it is anticipated that the market is ... registering a CAGR of 6.2% from 2014 to 2020. ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Calif., Oct. 6 PRO-DEX, INC. (Nasdaq: PDEX ... as Chief Financial Officer, effective October 6, 2010.  Mr. Hurwitz ... "Hal comes to Pro-Dex with a broad financial background ... with Coopers & Lybrand LLP, now part of PricewaterhouseCoopers LLP, ...
... DiFUSION Technologies Inc., a medical device company focused ... CleanFUZE™ anti-microbial technology for orthopedic implants, announced today ... of posterior interbody devices indicated for intervertebral body ... SI, in skeletally mature patients who have had ...
Cached Medicine Technology:Pro-Dex, Inc. Appoints Harold A. Hurwitz as Chief Financial Officer 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... Hartford, CT (PRWEB) October 25, 2014 Background: ... for Addiction Recovery (CCAR). He is a pioneer in the ... 30-year career in Connecticut's state treatment system and when he ... had nagged him while in public service. ... are making critical decisions concerning them? , 2. Can ...
(Date:10/25/2014)... October 25, 2014 Market ... Diagnostics Industry, 2009-2019 is a professional and ... Molecular Diagnostics industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Molecular Diagnostics listing their product ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific ... U.S. District Court, Southern District of West Virginia ... on Punitive Damages in a group of cases ... ruling issued on October 21st, U.S. District Judge ...
(Date:10/25/2014)... supply to an arm or a leg before heart surgery ... to a new study. "During heart surgery we ... be able to operate on it. After some time without ... energy because it doesn,t get oxygen. When we shut off ... arm or a leg, the body prepares for an upcoming ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2
... are more than twice as likely to have cardiovascular complications ... of a recent study. Steroids are widely used // to ... such as asthma, inflammatory bowel disease, and some types of ... used steroids between 1993 and 1996 and 82,202 people who ...
... disease risk factors, which include high blood pressure, impaired sugar ... condition is made if you have three out of five ... for cardiovascular disease. According to a new study, starting a ... extra risk. ,Based on findings of the study researchers ...
... with congenital heart disease are at a higher risk for ... these children early on has been difficult say researchers. ... a congenital heart problem called D-transposition of the great arteries ... The children were then tested for development and intelligence when ...
... with type 2 diabetes have a risk of developing ... for microaneurysms // in the eye, which are ... done in England shows good blood pressure control significantly ... which can ultimately lead to blindness. ,For ...
... in those with a genetic predisposition to the disease, ... and has a 4-percent five-year survival rate. Only a ... ,Researchers studied 826 patients with pancreatic cancer. Thirty of ... case the patient had a first-degree relative with the ...
... may be a new way to correct hard-to-treat birthmarks ... invasive surgical procedure, where literally lighting up the problem ... basically consist of enlarged veins. Most people with the ... the birthmarks get worse, resulting in disfigurement, functional impairment, ...
Cached Medicine News:
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
... Rusch Safety Clear Plus™ Cuffed Endotracheal Tube w. ... inside. Sterile, Single use. A quality Rusch endotracheal ... to use saving you time and storage space. ... facilitate smooth withdrawal. It is designed with a ...
Medicine Products: